[ad_1]
The National Institute of Hygiene "Rafael Rangel" (INHRR), an entity attached to the Ministry of Health, announced that They were taking preventative measures to remove from the market all products containing the active substance Valsartan, an ingredient used primarily for the treatment of high blood pressure and cardiovascular disease.
According to the alert published on the website of the Institute, the decision was taken after the information provided by the Spanish Agency for Drugs and Sanitarios Products (AEMPS) and the l & # 39; European Medicines Agency (EMA), according to which the presence of an impurity classified "probably carcinogenic" by the International Agency for Research on Cancer (IARC) was detected in the above-mentioned product. [19659003] The INHRR indicates that patients should not interrupt treatment. In case of consumption of a drug with the active ingredient in question, "they should contact their doctor to prescribe another drug with the same composition, or in its absence another alternative treatment. ".
In the case of health professionals, they should locate as much as possible the patients who prescribed Valsartan and inform them that not all products or lots are compromised.
The alert highlights the active ingredient provided by the pharmaceutical company Zhejiang Huahai Pharmaceuticals of China, and encourages representatives of the companies Laboratorios Klinos, CA, Vivax Pharmaceuticals Laboratories, CA, Laboratorios Leti SAV, Laboratorios Vargas, SA and Generic of Quality, GC, CA to immobilize distribution to pharmacies.
pointed out that pharmacists are urged not to offer products containing Valsartan alone or in combination with another active ingredient to be included in the lots concerned.
|| Courtesy VF
[ad_2]
Source link
